NCT07338370RECRUITINGanonymous

Relation Between Prostaglandin E2 Metabolite Levels and the Development of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Neonates

Sponsor

Source record

Ain Shams University

Phase

Source record

Not classified

Modality

AI-normalized

small molecule

Target

AI-normalized

Ibuprofen (Brufen®)

Indication / condition

AI-normalized

Neonatal Prematurity

Intervention

Source record

Ibuprofen (Brufen®)

Related intelligence directories

Indication directory: Neonatal Prematurity Modality directory: small molecule Target directory: Ibuprofen (Brufen®)

Source & freshness

Source record

NCT ID

NCT07338370

Original source

ClinicalTrials.gov

Source last updated

Jan 13, 2026

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT07338370

Title

Relation Between Prostaglandin E2 Metabolite Levels and the Development of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Neonates

Sponsor

Ain Shams University

Status

RECRUITING

Phase

Detailed source ingestion pending

Condition raw

Neonatal Prematurity, Patent Ductus Arteriosus in Preterm Infants, Prostaglandins

Condition normalized

Neonatal Prematurity, Patent Ductus Arteriosus in Preterm Infants, Prostaglandins

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Ibuprofen (Brufen®)

Target normalized

Ibuprofen (Brufen®)

Interventions

Ibuprofen (Brufen®)

Public preview

Source record

prospective observational cohort study to explore the relationship between PGE2 metabolite levels and the development of hemodynamically significant PDA in preterm neonates.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Relation Between Prostaglandin E2 Metabolite Levels and the Development of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Neonates

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT07338370

Status

RECRUITING

Phase

N/A

Sponsor

Ain Shams University

Executive brief

Investment-Ready Snapshot

prospective observational cohort study to explore the relationship between PGE2 metabolite levels and the development of hemodynamically significant PDA in preterm neonates.

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedJan 13, 2026

Internal syncJun 09, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT07338370

Indication

Neonatal Prematurity

Modality

small molecule

Target

Ibuprofen (Brufen®)

Intervention

Ibuprofen (Brufen®)

Source record